Use of amifostine in the therapy of osteosarcoma in children and adolescents

Show simple item record

dc.contributor.author Petrilli, A. S.
dc.contributor.author Oliveira, D. T.
dc.contributor.author Ginani, V. C.
dc.contributor.author Kechichian, R.
dc.contributor.author Dishtchekenian, A.
dc.contributor.author Roque, W. D.
dc.contributor.author Tanaka, C.
dc.contributor.author Dias, C. G.
dc.contributor.author Latorre, M. D.
dc.contributor.author Brunetto, A. L.
dc.contributor.author Cardoso, H.
dc.contributor.author Almeida, M. T.
dc.contributor.author Camargo, B. de
dc.date.accessioned 2016-01-24T12:33:18Z
dc.date.available 2016-01-24T12:33:18Z
dc.date.issued 2002-03-01
dc.identifier http://dx.doi.org/10.1097/00043426-200203000-00006
dc.identifier.citation Journal of Pediatric Hematology Oncology. Philadelphia: Lippincott Williams & Wilkins, v. 24, n. 3, p. 188-191, 2002.
dc.identifier.issn 1077-4114
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/26796
dc.description.abstract Amifostine protects normal tissue from the cytotoxic damage induced by radiation and chemotherapy. in this study. 39 consecutive newly diagnosed children with osteosarcoma were assessed; 20 received amifostine and 19 did not. the chemotherapy regimen included an induction phase of three cycles of cisplatin (100 mg/m(2)), carboplatin (500 mg/m(2)), and doxorubicin (60 mg/m(2)), followed by surgery. Alternating cycles of cisplatin/ifosfamide (9 mg/m(2)), ifosfamide/doxorubicin. carboplatin/doxorubicin, and ifosfamide/carboplatin were administered every 3 weeks to complete 26 weeks of treatment. Amifostine was administered 15 minutes before the infusions of cisplatin and carboplatin in a total of 193 infusions. Side effects during infusions and renal, hearing, and bone marrow toxicities were evaluated and compared between the two groups. Hypotension was observed in 28 (14.5%) infusions. No patient required discontinuation of therapy. Fewer than two episodes of vomiting occurred in 130 (71%) infusions and two to five episodes occurred in 51 (28%) infusions. and no patient had grade 4 toxicity. There was no difference between the two groups regarding renal toxicity (creatinine clearance). Neutropenia and leukopenia were significantly less frequent in the amifostine group. No difference was observed in platelet and hearing toxicities. Amifostine was well tolerated in doses of 740 mg/m(2) in children and adolescents, and myelotoxicity was less severe in the amifostine group. This was a pilot study for further evaluation in a larger randomized trial. en
dc.format.extent 188-191
dc.language.iso eng
dc.publisher Lippincott Williams & Wilkins
dc.relation.ispartof Journal of Pediatric Hematology Oncology
dc.rights Acesso restrito
dc.subject amifostine en
dc.subject children and adolescents en
dc.subject osteosarcoma en
dc.title Use of amifostine in the therapy of osteosarcoma in children and adolescents en
dc.type Artigo
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Hosp Clin Porto Alegre
dc.contributor.institution Universidade de São Paulo (USP)
dc.description.affiliation Universidade Federal de São Paulo, Escola Paulista Med, Dept Pediat, Pediat Oncol Inst, São Paulo, Brazil
dc.description.affiliation AC Camargo Hosp, Dept Pediat, São Paulo, Brazil
dc.description.affiliation Hosp Clin Porto Alegre, Dept Pediat, Porto Alegre, RS, Brazil
dc.description.affiliation Univ São Paulo, Childrens Inst, São Paulo, Brazil
dc.description.affiliation Univ São Paulo, Coll Publ Hlth, São Paulo, Brazil
dc.description.affiliation Universidade Federal de São Paulo, Dept Human Commun Disorders Orhorrinolaringol, São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Escola Paulista Med, Dept Pediat, Pediat Oncol Inst, São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Dept Human Commun Disorders Orhorrinolaringol, São Paulo, Brazil
dc.identifier.doi 10.1097/00043426-200203000-00006
dc.description.source Web of Science
dc.identifier.wos WOS:000174910300005



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account